Why FAP Is a Compelling Stromal Target in Solid Tumors
Fibroblast activation protein (FAP-α) is a type II transmembrane serine protease expressed in the stroma of more than 90% of common human epithelial cancers, yet is absent from normal adult quiescent tissue — a selectivity profile that creates an unusually wide therapeutic window for oncology drug developers. Patent evidence retrieved across this analysis consistently positions FAP as a tumor microenvironment (TME)-specific target, with expression confined to cancer-associated fibroblasts (CAFs) within solid tumors and not detected in benign tumors or healthy resting tissue.
The biological rationale for targeting FAP is grounded in the multifaceted role that FAP-expressing CAFs play in sustaining tumour growth. According to a patent filed by the University of Pennsylvania Board of Trustees, CAFs have “enhanced almost every aspect of tumor growth and spread,” functioning as physical barriers to drugs and immune cells, providing tumour growth signals, and exerting active immunosuppressive functions. This means eliminating or functionally reprogramming FAP-positive CAFs is expected to relieve TME-mediated immune suppression and sensitise solid tumours to cytotoxic and immune effector mechanisms — a rationale shared across every modality described in this report.
Fibroblast activation protein (FAP) is expressed in the stroma of more than 90% of common human epithelial cancers and is absent from normal adult quiescent tissue, establishing a favourable therapeutic index for FAP-targeted oncology agents.
Beyond FAP itself, retrieved patent evidence identifies several co-targeting strategies that exploit antigens co-expressed with FAP in distinct tumour compartments. These include mesothelin (on tumour epithelial cells), DR5/death receptor 5 (on tumour cells), CD40 (an immune-activating receptor), PSMA (prostate-specific membrane antigen, expressed in solid tumour neovasculature), and CEA (carcinoembryonic antigen). Each co-target reflects a distinct mechanistic hypothesis for how FAP anchoring can be converted into a therapeutic payload — from immune activation to direct apoptosis induction to radionuclide delivery.
Cancer-associated fibroblasts are stromal cells within solid tumours that overexpress FAP. They promote tumour growth and metastasis by creating physical barriers to immune cells and therapeutic agents, providing tumour growth signals, and exerting active immunosuppressive functions. FAP-targeted therapies aim to eliminate or reprogram these cells to restore immune access to the tumour.
CAR-T and CAR-iNKT Cell Engineering Against FAP
FAP-directed cellular therapies represent the most numerically prominent modality in the retrieved patent dataset, with at least four distinct patent filings describing engineered immune effector cells bearing anti-FAP chimeric antigen receptors (CARs). These constructs couple an FAP-binding scFv or VHH nanobody to intracellular CD3ζ and co-stimulatory domains — typically CD137/4-1BB — enabling MHC-independent recognition and killing of FAP-positive CAFs in solid tumours without requiring tumour antigen presentation.
FAP-targeted CAR-T cell constructs use anti-FAP scFv or VHH nanobodies coupled to CD3ζ and 4-1BB co-stimulatory domains to kill FAP-positive cancer-associated fibroblasts in an MHC-independent manner; at least four distinct patent filings covering this approach have been retrieved, all at preclinical development stages.
From Conventional T Cells to Fourth-Generation Armoured Constructs
The earliest retrieved FAP-targeted CAR-T filing in this dataset is a 2020 CN patent from West China Hospital, Sichuan University, describing a dual-target CAR simultaneously recognising mesothelin on tumour epithelial cells and FAP on CAFs, incorporating 4-1BB co-stimulation. The patent states that FAP binding “converts the inhibitory FAP signal into an activating signal,” enhancing T cell killing activity and proliferation. This dual-antigen strategy is designed to reduce antigen escape — a recognised failure mode for single-target CAR-T approaches in solid tumours, as documented by researchers publishing in journals such as Nature Medicine.
By 2023, Guangxi Medical University filed a CN patent describing a fourth-generation “armoured” CAR-T concept: a construct encoding an anti-FAP scFv fused to a secreted CTLA-4 VHH nanobody (FAP VHH-HIStag-CD8-CD137-CD3ζ-CTLA-4 VHH-GFP). This approach functionalises the CAR-T cell itself as a local checkpoint inhibitor delivery vehicle, combining direct cytotoxicity against FAP-positive cells with secretion of a CTLA-4 blocking nanobody to address Treg-mediated suppression within the FAP-rich TME. The patent states the construct exhibits “good killing of FAP-positive tumor cells” correlated with FAP expression levels.
The most recent cellular therapy innovation in this dataset comes from Mingke Therapeutics (2025 CN patent), which describes novel anti-FAP antibodies incorporated into CAR constructs expressed in invariant natural killer T (iNKT) cells rather than conventional αβ T cells. FAP-CAR iNKT cells demonstrated “in vitro killing of FAP-positive tumor cells” and “in vivo tumor control in a melanoma A-375-FAP+ cancer model,” with data showing improved persistence compared to conventional CAR-T formats. The iNKT cell format is notable because these cells combine innate-like rapid activation with adaptive-like cytotoxicity, potentially addressing the persistence limitations that have hampered CAR-T therapies in solid tumours.
“FAP-expressing cancer-associated fibroblasts have enhanced almost every aspect of tumor growth and spread, acting as barriers to drugs and immune cells.” — University of Pennsylvania Board of Trustees patent filing, CN 2022
The University of Pennsylvania Board of Trustees’ 2022 CN patent provides broader coverage of anti-FAP CAR compositions applicable to canine, murine, and human tumour-associated cells, explicitly proposing combination with checkpoint blockade, switch co-stimulatory receptors, or other CAR-T therapies. All four retrieved CAR-T filings are at preclinical stages, with in vitro and xenograft data only.
Explore the full FAP-targeted CAR-T patent landscape and assignee activity in PatSnap Eureka.
Search FAP Patents in PatSnap Eureka →Bispecific Antibody Formats: CD40, DR5, and PSMA Co-Targeting
Three distinct FAP-directed bispecific formats are captured in retrieved patent evidence, each exploiting FAP’s stromal selectivity for a different mechanistic purpose: concentrating immune activation (CD40), triggering apoptosis (DR5), and enabling dual-target radioligand imaging and therapy (FAP-α/PSMA). All three are attributed to Roche or Johns Hopkins University, indicating that large-scale commercial and academic IP strategies around FAP bispecifics are already well-established.
FAP×CD40: Localising Immune Agonism to the Tumour Stroma
A 2024 CN patent from F. Hoffmann-La Roche AG describes a bispecific antigen-binding molecule in a 2+1 configuration — bivalent for CD40, monovalent for FAP — designed to concentrate CD40 agonist activity within FAP-positive TMEs. Unconjugated CD40 agonist antibodies have historically caused systemic toxicity, including cytokine release and liver inflammation; FAP anchoring is intended to restrict dendritic cell and macrophage activation to the tumour stroma. Preclinical data in an orthotopic head-and-neck tumour mouse model (mEERL95) expressing FAP in the stroma showed activity as monotherapy and improved survival in combination with radiation therapy — a combination strategy with biological rationale supported by NIH-funded research into radiation-induced immunogenic cell death.
FAP×DR5: Stromal Anchoring to Overcome Hepatotoxicity
A 2021 CN patent from F. Hoffmann-La Roche AG covers bispecific antibodies containing at least one DR5-specific and at least one FAP-specific antigen-binding site. The mechanism exploits FAP-mediated stromal anchoring to cluster DR5 death receptors and trigger apoptosis within the tumour stroma and on tumour cells — addressing the systemic hepatotoxicity that has historically limited unconjugated DR5 agonist antibodies. Retrieved data indicate that “DR5-FAP antibody as a single agent resulted in 96% tumor growth inhibition,” and that combination with ifosfamide achieved complete tumour regression in xenograft models including a patient-derived sarcoma (Sarc4605) and DLD-1/3T3 colorectal model.
Roche’s FAP×DR5 bispecific antibody achieved 96% tumour growth inhibition as a single agent in xenograft models; combining it with ifosfamide produced complete tumour regression in patient-derived sarcoma (Sarc4605) and DLD-1/3T3 colorectal xenograft models, according to a 2021 CN patent filing.
FAP-α/PSMA: Dual Radioligand Theranostics
A 2023 CN patent from Johns Hopkins University describes small-molecule low-molecular-weight (LMW) compounds containing both FAP-α-selective and PSMA-selective targeting moieties, modified with optical dyes, radioactive metal chelate complexes, or other radiolabelled prosthetic groups. The patent explicitly positions these as “a platform for imaging and radiotherapy targeting FAP-α and PSMA,” addressing the pharmacokinetic limitations of antibody-based imaging agents — specifically slow clearance and non-specific organ uptake. PSMA is noted as expressed in the neovasculature of most solid tumours including lung, colon, pancreatic, renal, and melanoma cancers, broadening the applicability of this platform well beyond prostate cancer. Standards for radiolabelled compound development are monitored by bodies including IAEA.
Adaptor Molecules, Nanosystems, and Immunocytokines: Emerging FAP-Targeting Platforms
Beyond CAR-T cells and bispecific antibodies, three further FAP-targeting platforms are captured in retrieved patent evidence: a modular bispecific adaptor system enabling universal CAR-T cell redirection, a biomimetic PLGA nanosystem for dual anti-fibrotic and anti-senescence drug delivery to CAFs, and an FAP-anchored IL-2 immunocytokine designed to localise T cell expansion to the TME.
Universal CAR-T Adaptors: Decoupling Engineering from Targeting
A 2025 CN patent from Purdue Research Foundation describes bispecific adaptor molecules that bridge “universal” anti-FITC CAR-T cells (E2 CAR-T, recognising fluorescein) to FAP-positive tumour cells and cancer-associated fibroblasts via a FAP-targeting ligand conjugated to FITC through polyethylene glycol (PEG) linkers. In vivo data in MDA-MB-231-hFAP subcutaneous xenografts in NSG mice show that FAP8-PEG15-FITC “mediated better engagement with CAR-T cells in vivo” due to improved serum stability relative to shorter-linker comparators. This modular adaptor strategy decouples CAR-T engineering from target binding — enabling a single allogeneic anti-FITC CAR-T product to be redirected to FAP-expressing tumours via modular small-molecule adaptors, with potential cost and flexibility advantages over patient-specific FAP-CAR-T manufacturing.
Purdue Research Foundation’s FAP-FITC bispecific adaptor approach signals an emerging direction in which FAP-targeting is decoupled from CAR engineering. A single universal anti-FITC CAR-T product can be redirected to FAP-expressing tumours via modular small-molecule adaptors, potentially reducing manufacturing complexity compared to patient-specific FAP-CAR-T production.
FAP-Targeted Nanosystems for Dual Stromal Remodelling
A 2025 CN patent from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology describes FAP-CAR-CM@PLGA-AB nanoparticles: PLGA nanoparticles co-loaded with nintedanib (anti-fibrotic) and ABT-263/navitoclax (anti-senescence) encapsulated in a biomimetic shell derived from 4T1 cell membranes expressing an FAP scFv chimeric antigen receptor. The FAP scFv modification enhances CAF-targeted uptake and cytotoxicity, with retrieved data demonstrating cooperative cytotoxicity of ABT-263 and nintedanib against CAFs. The inventors propose this approach for breast cancer post-radiotherapy relapse prevention through dual CAF and senescent CAF clearance and TME derepression — a mechanistically distinct approach from immune-based strategies and potentially applicable to radiation-resistant disease.
FAP-Anchored IL-2 Immunocytokines
A 2019 JP patent from F. Hoffmann-La Roche AG describes tumour-targeted IL-2 variant immunocytokines binding FAP (or CEA) on tumour stroma, combined with anti-PD-L1 antibody. The mechanism leverages FAP expression to localise IL-2 cytokine activity to the TME, promoting T cell expansion selectively at the tumour site while minimising systemic IL-2 toxicity — a long-standing challenge in cytokine-based oncology, as documented by ASCO clinical guidelines on high-dose IL-2 regimens.
Track FAP nanosystem and immunocytokine patent activity across all jurisdictions with PatSnap Eureka.
Analyse FAP IP in PatSnap Eureka →Combination Strategies and the Evolving FAP-Targeted IP Landscape
Retrieved patent evidence signals a clear directional shift: FAP is no longer being pursued solely as a cytotoxic target but as an anchor for localised delivery of immunostimulatory, pro-apoptotic, and stroma-remodelling payloads. Multiple combination strategies are explicitly proposed or evidenced across the retrieved dataset, spanning checkpoint blockade, radiotherapy, chemotherapy, and modular cellular therapy platforms.
Checkpoint Blockade Integration
The University of Pennsylvania’s 2022 CN patent explicitly proposes combination with “immune-oncology antibody therapy and checkpoint blockade,” while Guangxi Medical University’s 2023 CN patent incorporates a secreted CTLA-4 nanobody directly into the CAR construct — functionalising the CAR-T cell as a local checkpoint inhibitor delivery vehicle. A separate JP patent from Merck KGaA (2021) covering a bifunctional anti-PD-L1/TGFβ trap fusion protein references FAP as a pharmacodynamic readout: the patent states that “anti-PD-L1/TGFβ trap significantly reduced FAP expression (p<0.0001)” and that combination with radiation therapy further reduced FAP expression (p=0.0054) in a stage III NSCLC mouse model — establishing FAP downregulation as a measurable endpoint for TME remodelling by TGFβ-targeting agents.
Radiotherapy Synergy
Roche’s FAP×CD40 bispecific patent (CN, 2024) presents preclinical data showing synergistic survival benefit when combining FAP×CD40 bispecific with radiation in the mEERL95 orthotopic head-and-neck model. Independently, the Merck KGaA anti-PD-L1/TGFβ data demonstrates that radiotherapy and TGFβ inhibition jointly downregulate FAP expression, suggesting additive stromal remodelling. The convergence of these signals across different assignees and mechanisms supports the hypothesis that radiation-induced stromal changes create a permissive context for FAP-targeted agents.
Assignee Landscape and Strategic Implications
F. Hoffmann-La Roche AG holds the most diversified FAP-bispecific IP in this dataset, with distinct patents covering FAP×CD40, FAP×DR5, and FAP-targeted IL-2 immunocytokine formats across CN and JP jurisdictions. IP strategists should monitor freedom-to-operate in FAP-bispecific combination formats, particularly formats linking FAP anchoring to immune agonism (CD40) or apoptosis induction (DR5). Academic institutions — West China Hospital, Guangxi Medical University, Johns Hopkins University, University of Pennsylvania, and Union Hospital (Huazhong University of Science and Technology) — drive FAP-CAR-T diversity and platform innovation, with CN-jurisdiction filings representing the majority of FAP-specific records in this dataset.
All FAP-targeted modalities captured in retrieved patent evidence — including CAR-T cells, bispecific antibodies, radioligand agents, and nanosystems — remain at preclinical development stages; no retrieved record references a clinical trial, IND filing, or patient efficacy data for any direct FAP-targeting agent described in this analysis.
The FAP-α/PSMA dual-targeting approach from Johns Hopkins (CN, 2023) represents an underexplored theranostic opportunity. The pharmacokinetic advantages of small-molecule agents over antibody-based radioligands — faster clearance, higher tumour-to-background ratios — suggest near-term IND-enabling potential, particularly as PSMA radioligand therapy enters mainstream use in prostate cancer following regulatory approvals monitored by bodies including the FDA. The dual FAP/PSMA platform could extend theranostic approaches to lung, colon, pancreatic, renal, and melanoma cancers where PSMA is expressed in tumour neovasculature. Global patent filing trends in radioligand therapy are tracked by WIPO as part of its annual technology trends reporting.
Across all modalities, preclinical evidence in this dataset is exclusively in vitro and murine. The absence of any retrieved clinical translation signals indicates that FAP-targeted modalities remain at early development stages — representing both an opportunity for first-mover IP advantage and a significant de-risking need for clinical proof-of-concept.